On February 6, 2015, the FDA approved a Genentech Medicine for the treatment of diabetic retinopathy in people with diabetic macular edema (DME).
On November 14, 2014, a Genentech medicine received FDA approval for use in a specific type of platinum-resistant ovarian cancer.
2014 ACR Annual Meeting
Presentations, Posters, and Papers galore. Check out our ACR 2014 newsroom to learn more about our commitment to rheumatology.
2014 AAO Annual Meeting
Genentech will present important new ophthalmic data at the 118th Annual Meeting of the American Academy of Ophthalmology (AAO) from October 18-21 in Chicago.
On October 15, 2014, the FDA approved a medicine for the treatment of idiopathic pulmonary fibrosis (IPF).
Genentech Agrees to Acquire Seragon to Strengthen Breast Cancer Pipeline
Read about Genentech’s planned acquisition of Seragon.
New Insights on Breast Cancer Research
With the recent acquisition of Seragon, Genentech is excited to add a new class of investigational medicines known as SERDs to our pipeline.
Sunshine Act: Increasing Transparency
Genentech fully supports efforts to increase transparency around the partnership between the industry and healthcare professionals.
Medicine for people with chronic idiopathic urticaria (CIU), a form of chronic hives.
Genentech is committed to ensuring price is not a barrier to access for patients. Learn about our programs.
Search for jobs. Learn more about what is currently available. And then apply for the position at Genentech that’s right for you.
Genentech named FORTUNE Best Company
We've been named to FORTUNE's "100 Best Companies to Work For" list for the 16th year in a row.
Clinical Trial Data Sharing
As part of our commitment to sharing data from our clinical trials, researchers may request access to analyzable patient-level data. Learn more.
We partnered on a survey that identified a significant gap in the understanding of diabetes and vision loss. Learn more.
Building Towards a Sustainable Future
In an effort to increase sustainability practices on our SSF campus, we've joined the US Green Buildings Challenge.